ClinicalThought


Share

Program Content

Activities

  • Melanoma Immunotherapy FAQ
    Experts Address Questions on the Use of Immunotherapy for Resectable and Unresectable Melanoma in Today’s Practice
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 19, 2023

Faculty

cover img faculity

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

cover img faculity

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

cover img faculity

Michael Postow, MD

Chief, Melanoma Service
Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb